On November 2, 2022, Werfen announced its agreement to acquire Immucor, Inc., a U.S.-based leader in transfusion and transplant diagnostics, for approximately $2 billion USD (about 2.74 billion CAD at the time). The transaction closed in March 2023, following regulatory approvals. This acquisition expanded Werfen's specialized diagnostics portfolio to include transfusion and transplant solutions, complementing its existing hemostasis, acute care, and autoimmunity segments. Immucor's Canadian subsidiary, Dominion Biologicals Ltd., based in Nova Scotia, enhanced Werfen's presence in Canada's diagnostics market. Legal advisors for the deal were Milbank LLP and Borden Ladner Gervais LLP for Werfen, and Ropes & Gray LLP for the sellers.